Melatonin. Comprehensive Profile

Profiles of Drug Substances, Excipients and Related Methodology

Volumn 38, Issue , 2013, Pages 159-226

  Al Omary, Fatmah A M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Antioxidant; Chromatographic analysis; Free radical scavenger; Jet lag; Melatonin; Spectroscopic analysis; Tryptophane; X ray diffraction

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; 5 HYDROXYTRYPTOPHAN; 6 HYDROXYMELATONIN; 6 HYDROXYMELATONIN O SULFATE; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ARACHIDONIC ACID; CYCLODEXTRIN; ERYTHROPOIETIN; FLUVOXAMINE; FOLLITROPIN; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HYDROGEN PEROXIDE; HYPNOTIC AGENT; IRON; LUTEINIZING HORMONE; MALONALDEHYDE; MELATONIN; MELATONIN RECEPTOR; NITRATE; NITRIC OXIDE SYNTHASE; NITRITE; RAMELTEON; SCAVENGER; SOMATOSTATIN; SUPEROXIDE DISMUTASE;

ANEMIA; ANTIOXIDANT ACTIVITY; ARTICLE; BEDTIME DOSAGE; BLOOD BRAIN BARRIER; CARBON NUCLEAR MAGNETIC RESONANCE; CARDIOVASCULAR DISEASE; CIRCADIAN RHYTHM; CLUSTER HEADACHE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE DISEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERGLYCEMIA; HYPNOSIS; IMMUNITY; INSOMNIA; JET LAG; LIPID PEROXIDATION; LIVER METABOLISM; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; MELTING POINT; MENTAL DISEASE; MIGRAINE; NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PHYSICAL CHEMISTRY; PINEALECTOMY; POLAROGRAPHY; POTENTIOMETRY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOIMMUNOASSAY; SEIZURE; SIGNAL TRANSDUCTION; SLEEP DISORDER; SLEEP QUALITY; SYNTHESIS; TITRIMETRY; ULTRAVIOLET SPECTROSCOPY; X RAY DIFFRACTION;

EID: 84878169146     PISSN: 18715125     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-407691-4.00005-8     Document Type: Chapter

References (322)

1. The Merck Index 1996, 1004. Merck and Co, New Jersey. 12th ed. S. Budavari (Ed.).
2. Martindale, The Extra Pharmacopeia 1999, 1599. Royal Pharmaceutical Society, London. 32nd ed. J.E.F. Reynold (Ed.).
3. Index Nominum 2000, International Drug Directory 2000, 642. Medpharm GmbH Scientific Publishers, Stuttgart. 17th ed. Swiss Pharmaceutical Society (Ed.).
4. Clarke's Analysis of Drugs and Poison 2004, 1151. Pharmaceutical Press, London. third ed. A.C. Moffat, D. Osselton, B. Widdop (Eds.).
5. Lee T.H., Lerner A.B., Buettner-Janusch V. Isolation and structure of human corticotropin (ACTH). J. Am. Chem. Soc. 1959, 81:6084.
6. Wakahara A. Crystal and molecular structure. Chem. Lett. 1972, 70:1139.
7. Lissoni P., Brivio F., Ardizzoia A., Tancini G., Barni S. Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status. Tumori 1993, 79:401.
8. Lissoni P., Barni S., Tancini G., Ardizzoia A., Ricci G., Aldeghi R., Brivio F., Tisi E., Rovelli F., Rescaldani R. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br. J. Cancer 1994, 69:196.
9. Bregani E.R., Lissoni P., Rossini F., Barni S., Tancini G., Brivio F., Conti A., Maestroni G.J. Prevention of interleukin-2-induced thrombocytopenia during the immunotherapy of cancer by a concomitant administration of the pineal hormone melatonin. Recenti Prog. Med. 1995, 86:231.
10. Short R.V. Melatonin. Br. Med. J. 1993, 307:952.
11. Cohen M., Small R.A., Brzezinski A. Hypotheses: melatonin/steroid combination contraceptives will prevent breast cancer. Breast Cancer Res. Treat. 1995, 33:257.
12. Pittalis S., Lissoni P., Giani L., Casati M., Kropacek N., Orfanò S., Giavolucci F., Merlini D. Effect of a chronic therapy with the pineal hormone melatonin on cholesterol levels in idiopathic hypercholesterolemic patients. Recenti Prog. Med. 1997, 88:401.
13. Leone M., D'Amico D., Moschiano F., Fraschini F., Bussone G. Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups. Cephalalgia 1996, 16:494.
14. Brzezinski A. Melatonin in humans. N. Engl. J. Med. 1997, 336:186.
15. Haimov I., Lavie P. Potential of melatonin replacement therapy in older patients with sleep disorders. Drugs Aging 1995, 7:75.
16. Brown G.M. Melatonin in psychiatric and sleep disorders: therapeutic implications. CNS Drugs 1995, 3:209.
17. Anonymous Melatonin. Med. Lett. Drugs Ther. 1995, 37:111.
18. Arendt J. Melatonin. Br. Med. J. 1996, 312:1242.
19. Lamberg L. Melatonin potentially useful but safety, efficacy remain uncertain. JAMA 1996, 276:1011.
20. Zhdanova I.V. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin. Pharmacol. Ther. 1995, 57:552.
21. Attenburrow M.E.J., Cowen P.J., Sharpley A.L. Low dose melatonin improves sleep in healthy middle-aged subjects. Psychopharmacology (Berl.) 1996, 126:179.
22. Garfinkel D., Laudon M., Nof D., Zisapel N. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 1995, 346:541.
23. Dahlitz M., Alvarez B., Vignau J., English J., Arendt J., Parkes J.D. Delayed sleep phase syndrome response to melatonin. Lancet 1991, 337:1121.
24. Lehmann E.D., Cockerell O.C., Rudge P. Somnolence associated with melatonin deficiency after pinealectomy. Lancet 1996, 347:323.
25. Middleton B.A., Stone B.M., Arendt J. Melatonin and fragmented sleep patterns. Lancet 1996, 348:551.
26. Waterhouse J., Reilly T., Atkinson G. Jet-Lag. Lancet 1997, 350:1611.
27. Petrie K., Dawson A.G., Thompson L., Brook R. A double-blind trial of melatonin as a treatment for jet lag in international cabin crew. Biol. Psychiatry 1993, 33:526.
28. Arendt J. Jet-Lag. Lancet 1998, 351:293.
29. Martindale, The Complete Drug Reference 1999, 1599. The Pharmaceutical Press, Chicago. 32 ed. S.C. Sweetman (Ed.).
30. Harman D. Role of antioxidant nutrients in aging: overview. Age 1995, 18:51.
31. Harman D. Free radical theory of aging: the free radical diseases. Age 1984, 7:111.
32. Taitou Y. Human aging and melatonin: clinical relevance. Exp. Gerontol. 2001, 36:1083.
33. Radogna F., Sestili P., Martinelli C., Paolillo M., Paternoster L., Albertini M.C., Accorsi A., Gualandi G., Ghibelli L. Lipoxygenase-mediated pro-radical effect of melatonin via stimulation of arachidonic acid metabolism. Toxicol. Appl. Pharmacol. 2009, 238:170.
34. Zang L.-Y., Cosma G., Gardner H., Vallyathan V. Scavenging of reactive oxygen species by melatonin. Biochim. Biophs. Acta 1998, 1425:469.
35. Claustrat B., Brun J., Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med. Rev. 2005, 9:11.
36. Tan D.X., Chen L.D., Poegeller B. A Potent endogenous hydroxyl radical scavenger. Endocr. J. 1993, 1:57.
37. Manev H., Uz T., Kharlamov A., Cagnoli C.M., Franceschini D., Giusti P. In vivo protection against kainate-induced apoptosis by the pineal hormone melatonin: effect of exogenous melatonin and circadian rhythm. Restor. Neurol. Neurosci. 1996, 9:251.
38. Herrera J., Nava M., Romero F., Rodriguez-Iturbe B. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am. J. Kidney Dis. 2001, 37:750.
39. Gitto E., Karbownik M., Reiter R.J., Tan D.X., Cuzzocrea S., Chiurazzi P., Cordaro S., Corona G., Trimarchi G., Barberi I. Effects of melatonin treatment in septic newborns. Pediatr. Res. 2001, 50:756.
40. Fulia F., Gitto E., Cuzzocrea S., Reiter R.J., Dugo L., Gitto P., Barberi S., Cordaro S., Barberi I. Increased levels of malondialdehyde and nitrite/nitrate in the blood of asphyxiated newborns: reduction by melatonin. J. Pineal Res. 2001, 31:343.
41. Velkov Z.A., Velkov Y.Zh., Galunska B.T., Paskalev D.N., Tadjer A.V. Melatonin: quantum-chemical and biochemical investigation of antioxidant activity. Eur. J. Med. Chem. 2009, 44:2834.
42. Touitou Y. Human aging and melatonin. Clinical relevance. Exp. Gerontol. 2001, 36:1083.
43. Ceraulo L., Ferrugia M., Tesoriere L., Segreto S., Livera M.A., Liveri T.V. Interactions of melatonin with membrane models: portioning of melatonin in AOT and lecithin reversed micelles. J. Pineal Res. 1999, 26:108.
44. Hardeland R., Balzer I., Poeggeler B., Fuhrberg U., Behmann G., Wolf R., Meyer T.J., Reiter R.J. On the primary functions of melatonin in evolution: mediation of photoperiodic signals in a unicell, photooxidation, and scavenging of free radicals. J. Pineal Res. 1995, 18:104.
45. Pozo D., Reiter R.J., Calvo J.R., Guerrero J.M. Physiological concentrations of melatonin inhibit nitric oxide synthase in rat cerebellum. Life Sci. 1994, 55:PL455.
46. Reiter R.J., Tan D.-X., Osuna C., Gitto E. Actions of melatonin in the reduction of oxidative stress. A review. J. Biomed. Sci. 2000, 7:444.
47. Pieri C., Moroni F., Marra M., Marcheselli F., Recchioni R. Melatonin is an efficient antioxidant. Arch. Gerontol. Geriat. 1995, 20:159.
48. Beyer C.E., Stekerre J.D., Saphier D. Antioxidant properties of melatonin-an emerging mystery. Biochem. Pharmacol. 1998, 56:1265.
49. Gulcin I., Buyukokuroglu M.E., Oktay M., Kufrevioglu O.I. On the in vitro antioxidative properties of melatonin. J. Pineal Res. 2002, 33:167.
50. Tan D.X., Hardeland R., Manchester L.C., Burkhard P., Silvia L.B., Mayo J.C., Sainz R.M., Reiter R.J. Mechanistic and comparative studies of melatonin and classic antioxidants in terms of their interactions with the ABTS cation radical. J. Pineal Res. 2003, 34:249.
51. Berra B., Rizzo A.M. Melatonin circardian rhythm regulator, chronobiotic, antioxidant and beyond. Prog. Neurobiol. 2008, 85:335.
52. Mahal H.S., Sharma H.S., Mukherjee T. Antioxidant properties of melatonin: a pulse radiolysis study. Free Radic. Biol. Med. 1999, 26:557.
53. Ma X., Idle J.R., Krausz K.W., Dun-Xian T., Ceraulo L., Gonzalez F.J. Urinary metabolites and antioxidant products of exogenous melatonin in the mouse. J. Pineal Res. 2006, 40:343.
54. Hardeland R., Pandi-Perumal S.R. Melatonin, a potent agent in antioxidative defense: actions as a natural food constituent, gastrointestinal factor, drug and prodrug. Nutr. Metab. 2005, 2:22.
55. Fusco D., Colloca G., Lo Monaco M.R., Cesari M. Effects of antioxidant supplementation on the aging process. Clin. Int. Aging 2007, 2:377.
56. Diplock A.T., Charleuk J.L., Crozier G., Kok F.J., Rice-Evans C., Roberfroid M., Stahl W., Vina Ribes J. Functional food science and defence against reactive oxidative species. Br. J. Nutr. 1998, 80:577.
57. Aydogan S., Yerer M.B., Goktos A. Melatonin and nitric oxide. J. Endocrinol. Invest. 2004, 29:281.
58. Fusco D., Colloca G.L.O., Lo Monaco M.R., Cesari M. Effects of antioxidant supplementation on the aging process. Clin. Interv. Aging 2007, 2:377.
59. Tan D.X., Reiter R.J., Manchester L.C., Yan M.T., El-Sawi M., Sainz R.M., Mayo J.C., Kohen R., Allegra M., Hardeland R. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr. Top. Med. Chem. 2002, 2:197.
60. Tan D.X., Manchester L.C., Reiter R.J., Oi W.B., Karbownik M., Calvo J.R. Significance of melatonin in antioxidative defense system: reactions and products. Biol. Signals Recept. 2000, 9:137.
61. Tan D.X., Reiter R.J., Manchester L.C., Yan M.T., El-Sawi M., Sainz R.M., Mayo T.C., Kohen R., Allegra M., Hardeland R. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr. Top. Med. Chem. 2002, 2:181.
62. Hardeland R., Pandi-Perumal S.R. Melatonin, a potent agent in antioxidative defense: actions as a natural food constituent, gastrointestinal factor, drug and prodrug. Nutr. Metab. (Lond.) 2005, 10:22.
63. Tan D.X., Manchester L.C., Reiter R.J., Oi W.B., Karbownik M., Calvo J.R. Significance of melatonin in antioxidative defense system: reactions and products. Biol. Signals Recept. 2000, 9:137.
64. Tan D.X., Hardeland R., Manchester L.C., Poeggeler B., Lopez-Burillo S., Mayo J.C., Sainz R.M., Reiter R.J. Mechanistic and comparative studies of melatonin and classic antioxidants in terms of their interactions with the ABTS cation radical. J. Pineal Res. 2003, 34:249.
65. Tan D.X., Reiter R.J., Manchester L.C., Yan M.T., El-Sawi M., Sainz R.M., Mayo J.C., Kohen R., Allegra M., Hardeland R. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr. Top. Med. Chem. 2002, 2:160.
66. Tan D.X., Manchester L.C., Reiter R.J., Oi W.B., Karbownik M., Calvo J.R. Significance of melatonin in antioxidative defense system: reactions and products. Biol. Signals Recept. 2000, 9:137.
67. Tan D.X., Hardeland R., Manchester L.C., Poeggeler B., Lopez-Burillo S., Mayo J.C., Sainz R.M., Reiter R.J. Mechanistic and comparative studies of melatonin and classic antioxidants in terms of their interactions with the ABTS cation radical. J. Pineal Res. 2003, 34:249.
68. Hardeland R., Pandi-Perumal S.R. Melatonin, a potent agent in antioxidative defense: actions as a natural food constituent, gastrointestinal factor, drug and prodrug. Nutr. Metab. (Lond.) 2005, 10:22.
69. Poeggeler B., Thuermann S., Dose A., Schoenke M., Burkhardt S., Hardeland R. Melatonin's unique radical scavenging properties-roles of its functional substituents as revealed by a comparison with its structural analogs. J. Pineal Res. 2002, 33:20.
70. Tan D.X., Reiter R.J., Manchester L.C., Yan M.T., El-Sawi M., Sainz R.M., Mayo T.C., Kohen R., Allegra M., Hardeland R. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr. Top. Med. Chem. 2002, 2:181.
71. Tan D.X., Manchester L.C., Reiter R.J., Oi W.B., Karbownik M., Calvo J.R. Significance of melatonin in antioxidative defense system: reactions and products. Biol. Signals Recept. 2000, 9:137.
72. Tan D.X., Reiter R.J., Manchester L.C., Yan M.T., El-Sawi M., Sainz R.M., Mayo T.C., Kohen R., Allegra M., Hardeland R. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr. Top. Med. Chem. 2002, 2:97.
73. Vollrath I. The Pineal Organ 1981, Springer, Berlin.
74. Szmuszkovicz J., Anthony W., Heinzelman R. Synthesis of N-acetyl-5-methoxytryptamine. J. Org. Chem. 1960, 25:857.
75. Circadian Rhythms in the Pineal Gland 1979, 203. Raven Press, New York. D.T. Krieger (Ed.).
76. Photoperiodism, Melatonin and Pineal 1985, 38. Pitman, London. D. Evered, S. Clark (Eds.).
77. Claustrat B., Brun J., Ghazot G. The basic physiology and pathophysiology of melatonin. Sleep Med. Rev. 2005, 9:11.
78. Wurtman R.J., Axelrod J., Chu E.W. Melatonin, a pineal substance: effect on the rat ovary. Science 1963, 141:277-278.
79. Lerner A.B., Case J.D., Takahashi Y., Lee T.H., Mori W. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J. Am. Chem. Soc. 1958, 80:2587.
80. Boutin J.A., Audinot V., Ferry G., Delagrange P. Molecular tools to study melatonin pathways and actions. Trends Pharmacol. Sci. 2005, 26:412.
81. Ganguly S., Coon S.L., Klein D.C. Control of melatonin synthesis in the mammalian pineal gland: the critical role of serotonin acetylation. Cell Tissue Res. 2002, 309:127.
82. Itoh M.T., Ishizuka B., Kuribayashi Y., Amemiya A., Sumi Y. Melatonin, its precursors, and synthesizing enzyme activities in the human ovary. Mol. Hum. Reprod. 1999, 5:402.
83. Huilan H., Yang J. Huagong Shikan 2003, 17:30.
84. Somei M., Oshikiri N., Hasegawa M., Yamada F. Preparations of melatonin and 1-hydroxymelatonin, and its novel nucleophilic dimerization to (±)-3a,3a'-bispyrrolo[2,3-b]indoles. Heterocycles 1999, 51:1237.
85. Hugel H.M., Nurlawis F. Short syntheses of melatonin. Heterocycles 2003, 60:2349.
86. Yan M., Ma X., Wang J. Huaxue Jiaoyu 2007, 28:1.
87. Sun L., Hu J., Chen S., Dai Q. Beij. Gong. Dac. Xue. 1997, 23:22.
88. Melatonin Hypothesis 1997, 25. Battelle Press, Columbus, OH. R.G. Stevens, B.W. Wilson, L.E. Anderson (Eds.).
89. Prabhakar C., Kumar M.V., Reddy M.R., Sarma M.R., Reddy G.O. Org. Process Res. Dev. 1999, 3:155.
90. Huang L., Chen H., Tian Y. Guangzhou Huane 2000, 25:49.
91. Ackermann K., Stehle J. Melatonin synthesis in the human pineal gland: advantages, implications, and difficulties. Chronobiol. Int. 2006, 23:69.
92. Belyakova L.A., Varvarin A.M., Lyasnenko D.Yu., Khora O.V. Designing adsorption centres for biological active molecules on a silica surface. Adsorpt. Sci. Technol. 2005, 23:703.
93. Borisenkov M.F. Effect of natural light during " white nights" and melatonin on circadian rhythm of total antioxidant capacity of human saliva. Adv. Gerontol. Gerontol. Obsch. 2007, 20:76.
94. Florio G.M., Zwier T.S. 2001, Chicago, IL, August 26-30, PHYS. 346.
95. Zhang W.J., Bjorn L.O. The effect of ultraviolet radiation on the accumulation of medicinal compounds in plants. Fitoterapia 2009, 80:207.
96. Xiang R.X., Li X.Y., Li X.Z., Li H.B. Sep. Purif. Technol. 2009, 5:120.
97. Cojocel C., Novotny L., Vachalkova A., Knauf B. Comparison of the carcinogenic potential of streptozotocin by polarography and alkaline elution. Neoplasma 2003, 50:110.
98. Lang U., Kornemark M., Aubert M.L., Paunier L., Sizonenko P.C. Radioimmunological determination of urinary melatonin in humans: correlation with plasma levels and typical 24-hour rhythmicity. J. Clin. Endocrinol. Metab. 1981, 53:645.
99. Nielsen F.S., Hansen H.P., Jacobsen P., Rossing P., Smidt U.M., Christensen N.J., Pevet P., Vivien-Roels B., Parving H.H. Diabetic medicine. Br. Diabetes Assoc. 1999, 16:555.
100. Rebollar P.G., Ubilla E., Peleteiro J.B., Agapito M.T., Alvarino J.M. Determination of plasma melatonin levels by enzyme-linked immunosorbent assay (EIA) in turbot (Scophtalmus maximus L.) and tench (Tinca tinca L.). J. Physiol. Biochem. 1999, 55:341.
101. Cernuda-Cernuda R., Huerta J.J., Munoz U.M., Alvarez-Uria M., Garcia-Fernandez J.M. Age-related morphometric changes in the pineal gland. A comparative study between C57BL/6J and CBA mice. Histol. Histopathol. 2000, 15:1087.
102. Corujo-Auntuna J.L., Abad-Villar E.M., Fernández-Abedul M.T., Costa-Garia A.C. Voltammetric and flow amperometric methods for the determination of melatonin in pharmaceuticals. J. Pharm. Biomed. Anal. 2003, 31:421.
103. Miyamoto M., Nishikawa H., Doken Y., Hirai K., Uchikawa O., Ohkawa S.M. The sleep-promoting action of ramelteon (TAK-375) in freely moving cats. Sleep 2004, 27:1319.
104. Patrycja B., Pawel W., Agnieszka S., Maria W.-J., Janusz S., Krzysztof S., Krystyna S.-M. Pol. Merk. Lek. Org. Pols. Towar. Lekar 2007, 22:369.
105. Mang-Hung T., I-Hua W., Ya-Fen J.-S., Jia J.M., Miau-Hwa K., Hui-Min C., Ching-Hsiang W. Neurosci. Res. 2008, 60:233.
106. Huai-gang Q., Shao-wu C., Rong-bo T., Ze-liang L., Wan-long L., Hua-qiao W., Zhi-bin Y., Hong-wen H. Effects of the aqueous extract of the Chinese medicine Danggui-Shaoyao-San on rat pineal melatonin synthesis. Neuroendocrinol. Lett. 2008, 29:366.
107. Greer M., Williams C.M. Gas-chromatographic determination of melatonin and 6-hydroxymelatonin. Clin. Chim. Acta 1967, 15:165.
108. Degen P.H., DoAmaral J.R., Barchas J.D. A gas-liquid chromatographic assay of melatonin and indoleamines using heptafluorobutyryl derivatives. Anal. Biochem. 1972, 45:634.
109. Wilson B.W., Snedden W., Silman R.E., Smith I., Mullen P. A gas chromatography-mass spectrometry method for the quantitative analysis of melatonin in plasma and cerebrospinal fluid. Anal. Biochem. 1977, 81:283.
110. Balemans M., Juillard M.T., Van Benthem J., Collin J.P. Retention of indoles in the pineal organ of the bird (Melopsittacus undulatus, Shaw) during its preparation for radioautographic study. Biol. Cell 1983, 49:257.
111. Van Haard P.M. Chromatography of urinary indole derivatives. J. Chromatogr. 1988, 429:59.
112. Chin J.R. Determination of six indolic compounds, including melatonin, in rat pineal using high-performance liquid chromatography with serial fluorimetric-electrochemical detection. J. Chromatogr. 1990, 528:111.
113. Vitale A.A., Ferrari C.C., Aldana H., Affanni J.M. Highly sensitive method for the determination of melatonin by normal-phase high-performance liquid chromatography with fluorometric detection. J. Chromatogr. B 1996, 681:381.
114. Bechgaard E., Lindhardt K., Martinsen L. High-performance liquid chromatographic analysis of melatonin in human plasma and rabbit serum with on-line column enrichment. J. Chromatogr. B Biomed. Sci. Appl. 1998, 712:177.
115. Costantini A., Paoli F. Melatonin: quantitative analysis in pharmaceutical oral dosage forms using thin-layer chromatography (TLC) densitometry. Farmaco 1998, 53:443.
116. Covaci A., Doneanu C., Aboul-Enein H.Y., Schepens P. Determination of melatonin in pharmaceutical formulations and human plasma by gas chromatography-electron impact mass spectrometry. Biomed. Chromatogr. 1999, 13:431.
117. Toraño J.S., Rijn-Bikker P.V., Merksu P., Guchelaar H.J. Quantitative determination of melatonin in human plasma and cerebrospinal fluid with high-performance liquid chromatography and fluorescence detection. Biomed. Chromatogr. 2000, 14:306.
118. Daya S., Walker R.B., Glass B.D., Anoopkumar-Dukie S. The effect of variations in pH and temperature on stability of melatonin in aqueous solution. J. Pineal Res. 2001, 31:155.
119. Nunez-Vergara L.J., Squella J.A., Sturm J.C., Haez H., Camargo C. Simultaneous determination of melatonin and pyridoxine in tablets by gas chromatography-mass spectrometry. J. Pharm. Biomed. Anal. 2001, 26:929.
120. Rolcik J., Lerobei R., Siglerova V., Strnad M. Isolation of melatonin by immunoaffinity chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2002, 775:9.
121. Eriksson K., Ostin A., Levin J.O. Quantification of melatonin in human saliva by liquid chromatography-tandem mass spectrometry using stable isotope dilution. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2003, 794:115.
122. Romsing S., Ulfberg J., Bergqvist Y. Determination of melatonin in saliva using automated solid-phase extraction, high-performance liquid chromatography and fluorescence detection. Scand. J. Clin. Lab. Invest. 2008, 36:81.
123. Iizuka H., Yajima T. Potassium hexacyanoferrate(III)-mediated fluorometric determination of melatonin. Adv. Exp. Med. Biol. 2003, 527:587.
124. Zhang L., Zhong L. Dong. Dax. Xue, Yixueban 2003, 22:290.
125. Pucci V., Ferranti A., Mandrioli R., Raggi M.A. Determination of melatonin in commercial preparations by micellar electrokinetic chromatography and spectrofluorimetry. Anal. Chim. Acta 2003, 488:97.
126. Hamase K., Hirano J., Kosai Y., Tomita T., Zaitsu K. A sensitive internal standard method for the determination of melatonin in mammals using precolumn oxidation reversed-phase high-performance liquid chromatography. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2004, 811:237.
127. Yang X., Wang J., Zhang Z. Hua. Fen. Jili. 2004, 13:86.
128. Martinez G.R., Almeidda E.A., Klitzke C.F., Onuki J., Prado F.M., Medeiros M.H.G., Di Mascio P. Measurement of melatonin and its metabolites: importance for the evaluation of their biological roles. Endocrine 2005, 27:111.
129. Pobozy E., Michalski A., Sotowska-Brochocka J., Trojanowicz M. Determination of melatonin and its precursors and metabolites using capillary electrophoresis with UV and fluorometric detection. J. Sep. Sci. 2005, 28:2165.
130. Todoroki K., Ishimaru K., Yoshida H., Yoshitake T., Nohta H., Yamaguchi M. Simultaneous liquid chromatographic measurement of melatonin and related indoles through post-column electrochemical demethylation and fluorescence derivatization. Anal. Sci. 2006, 22:281.
131. Romsing S., Ulfberg J., Bergqvist Y. Determination of melatonin in human plasma with solid-phase extraction, high-performance liquid chromatography and fluorescence detection. Scand. J. Clin. Lab. Invest. 2003, 63:81.
132. Varvaresou A., Tsirivas E., Iakovou K., Gikas E., Papathomas Z., Vonaparti A., Panderi I. Development and validation of a reversed-phase ion-pair liquid chromatography method for the determination of magnesium ascorbyl phosphate and melatonin in cosmetic creams. Anal. Chim. Acta 2006, 573:284.
133. Cao J., Murch S.J., O'Brien R., Saxena P.K. Rapid method for accurate analysis of melatonin, serotonin and auxin in plant samples using liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 2006, 1134:333.
134. Varvaresou A., Tsaoula E., Tsirivas E. The influence of the addition of melatonin to a magnesium ascorbyl phosphate-containing formulation on the mechanical properties of human skin. Rev. Clin. Pharmac. Pharmacok. Int. Ed. 2003, 17:177.
135. Ayano E., Suzuki Y., Kanezawa M., Sakamoto C., Murase Y.M., Nagata Y., Kanazawa H., Kikuhci A., Okano T. Analysis of melatonin using a pH- and temperature-responsive aqueous chromatography system. J. Chromatogr. A 2007, 1156:213.
136. Wojclak-Kosior M., Wozniak A. Herb. Polo. 2008, 54:13.
137. Agarwal S.P., Gonsalves H.J., Khar R.K. HPTLC method for the analysis of melatonin in bulk and pharmaceutical formulations. Asian J. Chem. 2008, 31:1851.
138. Saracino M.A., Mercolini L., Musenga A., Bugamelli F., Raggi M.A. Comparison of analytical methods for the quality control of a new formulation containing soy extract and melatonin. J. Sep. Sci. 2008, 31:1851.
139. Munoz J.L.P., Ceinos R.M., Soengas J.L., Miguez J.M. A simple and sensitive method for determination of melatonin in plasma, bile and intestinal tissues by high performance liquid chromatography with fluorescence detection. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2009, 877:2173.
140. Dreux C. Studies on the biochemistry of the methoxyindoles. Spectrofluorometric determination of N-acetyl-5-methoxytryptamine (melatonin). Clin. Chim. Acta 1969, 23:177.
141. Cardinali D.P., Wurtman R.J. Methods for assessing the biological activity of the mammalian pineal organ. Methods Enzymol. 1975, 39:376.
142. Kasama T., Seyama Y., Yamakawa T., Mori W. Iy. Mas. Ken. Koen. 1978, 3:143.
143. Wilson B.W., Snedden W., Sillman R.E., Smith I., Mullen P. A gas chromatography-mass spectrometry method for the quantitative analysis of melatonin in plasma and cerebrospinal fluid. Anal. Biochem. 1977, 81:283.
144. Lang U., Korenemark M., Aubert M.L., Paunier L., Sizonenko P.C. Radioimmunological determination of urinary melatonin in humans: correlation with plasma levels and typical 24-hour rhythmicity. J. Clin. Endocrinol. Metab. 1981, 53:645.
145. Dalery J., Claustrat B., Brun J., Terra J.L., Chasot G., de Villard R. Daily profiles of melatonin, cortisol and gonadotropins in 8 adolescents with anorexia nervosa. Encéphale 1985, 11:25.
146. Tsang C.W., Pang S.F., Wong C.D. Adv. Pineal Res. 1989, 3:181.
147. Vieira R., Miguez J., Lema M., Aldegunde M. Pineal and plasma melatonin as determined by high-performance liquid chromatography with electrochemical detection. Anal. Biochem. 1992, 205:300.
148. Chou S.-T., Perng T.-F. Yao. Ship. Fenx. 1997, 5:131.
149. Chanut E., Nguyen-Legros J., Versaux-Botteri C., Trouvin J.-H., Launay J.-M. Determination of melatonin in rat pineal, plasma and retina by high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B Biomed. Sci. Appl. 1998, 709:11.
150. Lewy A.J. The dim light melatonin onset, melatonin assays and biological rhythm research in humans. Biol. Signal Recept. 1999, 8:79.
151. Simonin G., Bru L., Lelievre E., Jeanniot J.P., Bromet N., Walther B., Boursier-Neyret C. Determination of melatonin in biological fluids in the presence of the melatonin agonist S 20098: comparison of immunological techniques and GC-MS methods. J. Pharm. Biomed. Anal. 1999, 21:591.
152. Treatise Pineal Gland Melatonin 2002, 353. C. Haldar, M. Singaravel, S.K. Maitra (Eds.).
153. Corujo-Antuna J.L., Martinez-Montequin S., Fernandez-Abedul M.T., Costa-Garcia A. Sensitive adsorptive stripping voltammetric methodologies for the determination of melatonin in biological fluids. Electroanalysis 2003, 15:773.
154. Rozov S.V., Filatova E.V., Orlov A.A., Volkova A.V., Zhloba A.R.A., Blashko E.L., Pozdeyev N.V. N1-acetyl-N2-formyl-5-methoxykynuramine is a product of melatonin oxidation in rats. J. Pineal Res. 2003, 35:245.
155. Scheer F.A.J.L., Van Montfrans G.A., van Someren E.J.W., Mairuhu G., Buijs R.M. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 2004, 43:192.
156. Hamase K., Hirano J., Kosai Y., Tomita T., Zaitsu K. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2004, 811:237.
157. Minami M., Takahashi H., Inagaki H., Yamano Y., Onoue S., Matsumoto S., Sasaki T., Sakai K. Novel tryptamine-related substances, 5-sulphatoxydiacetyltryptamine, 5-hydroxydiacetyltryptamine, and reduced melatonin in human urine and the determination of those compounds, 6-sulphatoxymelatonin, and melatonin with fluorometric HPLC. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2009, 877:814.
158. Cavallo A., Hassan M. Stability of melatonin in aqueous solution. J. Pineal Res. 1995, 18:90.
159. Lee B.-J., Choi H.-G., Kim C.-K., Parrott K.A., Ayres J.W., Sack R.L. Solubility and stability of melatonin in propylene glycol and 2-hydroxypropyl-beta-cyclodextrin vehicles. Arch. Pharm. Res. 1997, 20:560.
160. Benloucif S., Gulco M.J., Reid K.J., Wolfe L.F., L'Hermite-Balenaux M., Zee P.C. Stability of melatonin and temperature as circadian phase markers and their relation to sleep times in humans. J. Biol. Rhythm. 2005, 20:178.
161. Schaffazick S.R., Pohlmann A.R., Guterres S.S. Nanocapsules, nanoemulsion and nanodispersion containing melatonin: preparation, characterization and stability evaluation. Pharmazie 2007, 62:354.
162. Dubey V., Mishra D., Jain N.K. Melatonin loaded ethanolic liposomes: physicochemical characterization and enhanced transdermal delivery. Eur. J. Pharm. Biopharm. 2007, 67:398.
163. Lane E.A., Moss H.B. Pharmacokinetics of melatonin in man: first pass hepatic metabolism. J. Clin. Endocrinol. Metab. 1985, 61:1214.
164. Kennaway D.J., Royles P., Dunstan E.A., Hugel H.M. Prolactin response in Border-Leicester x merino ewes to administration of melatonin, melatonin analogues, a melatonin metabolite and 6-methoxybenzoxazolinone. Aust. J. Biol. Sci. 1986, 39:427.
165. English J., Bojkowski C.N., Poulton A.L., Symons A.M., Arendt J. Short-term variations of circulating melatonin in the ewe. J. Pineal Res. 1987, 4:351.
166. Proceedings of 3rd European Congress on Biopharmacology and Pharmacokinetics 1987, vol. 2:675. I.V. Golovanov, A.B. Shteinpress, T.A. Guskova, M.M. Vigdorchik, J.M. Aiache, J. Hirtz (Eds.).
167. Mallo C., Zaidan R., Galy G., Vermeulen E., Brun J., Chazot G., Claustrat B. Pharmacokinetics of melatonin in man after intravenous infusion and bolus injection. Eur. J. Clin. Pharmacol. 1990, 38:297.
168. 11C]melatonin in humans. Nucl. Med. Biol. 1991, 183:357.
169. Cavallo A., Ritschel W.A. Pharmacokinetics of melatonin in human sexual maturation. J. Clin. Endocrinol. Metab. 1996, 815:1882.
170. Yeleswaram K., McLaughlin L.G., Knipe J.O., Schabdach D. Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications. J. Pineal Res. 1997, 22:45.
171. Huether G., Messner M., Rodenbeck A., Hardeland R. Effect of continuous melatonin infusions on steady-state plasma melatonin levels in rats under near physiological conditions. J. Pineal Res. 1998, 24:146.
172. Bechgaard E., Lindhardt K., Martinsen L. Intranasal absorption of melatonin in vivo bioavailability study. Int. J. Pharm. 1999, 182:1.
173. Hartter S., Grozinger M., Weigmann H., Roschke J., Hiemke C. Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin. Pharmacol. Ther. 2000, 67:1.
174. Hartter S., Nordmark A., Rose D.M., Bertilsson L., Tybring G., Laine K. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br. J. Clin. Pharmacol. 2003, 56:679.
175. Mao S., Chen J., Wei Z., Lku J., Bi D. Intranasal administration of melatonin starch microspheres. Int. J. Pharm. 2004, 272:37.
176. Cheung R.T.F., Tipoe G.L., Tam S., Kwan M.E.S., Zou L.Y., Chan P.S. Preclinical evaluation of pharmacokinetics and safety of melatonin in propylene glycol for intravenous administration. J. Pineal Res. 2006, 41:337.
177. Tsakalozou E., Markantonis-Kyroudis S. Pharmakeutike 2006, 19:9.
178. Greenblatt D.J., Harmatz J.S., Karim A. Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J. Clin. Pharmacol. 2007, 47:485.
179. Hilli J., Korhonen T., Turpeinen M., Hokkanen J., Mattia S., Laine K. The effect of oral contraceptives on the pharmacokinetics of melatonin in healthy subjects with CYP1A2 g.-163C>A polymorphism. J. Clin. Pharmacol. 2008, 48:986.
180. Xu T.-J., Wei W., Xu W.-p., Yang S.-X. Zhong. Xin. Zaz. 2008, 17:212.
181. Charles B., Touitou Y., Selmaoui B. A population pharmacokinetic turnover and surge-function model for describing melatonin biological rhythm in healthy male subjects. J. Pharm. Sci. 2009, 98:782.
182. Taitou Y. Clin. Relevance Exp. Gerontol. 2001, 36:1083.
183. Zhdanova I.V., Wurtman R.J., Morabito C., Piotrovska V.R., Lynch H.J. Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. Sleep 1996, 19:423.
184. Waldhauser F., Waldhauser M., Lieberman H.R., Deng M.H., Lynch H.J., Wurtman R.J. Bioavailability of oral melatonin in humans. Neuroendocrinology 1984, 39:307.
185. Guardiola-Lemaitre B. Toxicology of melatonin. J. Biol. Rhythms 1997, 12:697.
186. Melatonin and the Pineal Gland: From Basic Science to Clinical Application 1993, 99. Elsevier, Amsterdam. Y. Toulou, J. Arendit, P. Pévet (Eds.).
187. Reinberg A.E., Touitou Y. Synchronization and dyschronism of human circadian rhythms. Pathol. Biol. 1996, 44:487.
188. Lewy A.J., Wehr T.A., Goodwin F.K., Newsome D.A., Markey S.P. Light suppresses melatonin secretion in humans. Science 1980, 210:1267.
189. Bruno C., Jocelyne B., Guy C. Sleep Med. Rev. 2005, 1:11.
190. Kveder S., Mcisaac W.M. The metabolism of melatonin (N-acetyl-5-methoxytryptamine) and 5-methoxytryptamine. J. Biol. Chem. 1961, 326:3214.
191. Taborsky R.G., Delvigs P., Page I.H. 6-Hydroxyindoles and the metabolism of melatonin. J. Med. Chem. 1965, 6:855.
192. Wurthman R.J., Axelarod J., Antron-Tay F. Inhibition of the metabolism of H3-melatonin by phenothiazines. J. Pharmacol. Exp. Ther. 1968, 161:367.
193. Hirata F., Hayaishi O., Tokuyama T., Saeno S. In vitro and in vivo formation of two new metabolites of melatonin. J. Biol. Chem. 1974, 249:1311.
194. Ritta M.N., Cardinali D.P. Effect of indomethacin on monoamine metabolism and melatonin synthesis in rat pineal gland. Horm. Res. 1980, 12:305.
195. Weinberg U. Evidence that melatonin retention by the neonatal rat is greatly increased as compared to the adult: a novel biochemical mechanism. Brain Res. 1981, 217:221.
196. Bartness T.J., Wade G.N. Photoperiodic control of body weight and energy metabolism in Syrian hamsters (Mesocricetus auratus): role of pineal gland, melatonin, gonads, and diet. Endocrinology 1984, 114:492.
197. Aldhous M., Franey C., Wright J., Arendt J. Plasma concentrations of melatonin in man following oral absorption of different preparations. Br. J. Clin. Pharmacol. 1985, 19:517.
198. Pierce M.E., Besharse J.C. Melatonin and rhythmic photoreceptor metabolism: melatonin-induced cone elongation is blocked at high light intensity. Brain Res. 1987, 405:400.
199. Beedham C., Smith J.A., Steele D.L., Wright P.A. Chlorpromazine inhibition of melatonin metabolism by normal and induced rat liver microsomes. Eur. J. Drug Metab. Pharmacokinet. 1987, 12:299.
200. Cahill G.M., Besharse J.C. Retinal melatonin is metabolized within the eye of xenopus laevis. Proc. Natl. Acad. Sci. USA 1989, 86:1098.
201. Le Bars D., Thivolle P., Vitte P.A., Bojkowski C., Chazot G., Arendt J., Frackowiak R.S.J., Claustrat B. PET and plasma pharmacokinetic studies after bolus intravenous administration of [11C]melatonin in humans. Int. J. Rad. Appl. Instrum. B 1991, 18:357.
202. Grace M.S., Cahill G.M., Besharse J.C. Melatonin deacetylation: retinal vertebrate class distribution and Xenopus laevis tissue distribution. Brain Res. 1991, 559:56.
203. Patel M.M., Ramachandran A.V. In vitro influence of hormones on transport of glucose and glycogen in liver and muscle of pinealectomised pigeons, Columba livia Gmellin. Indian J. Exp. Biol. 1992, 30:211.
204. Bartsch C., Prast G., Peters C., Bartsch H., Mecke D., Lippert T.H. Int. Congr. Ser. 1993, 1017:317.
205. Melatonin in the Promotion of Health 1999, 69. CRC Press, New York. R.R. Watson (Ed.).
206. Ursing C., Hartter S., Von Bahr C., Tybring G., Bertisson L., Rojdmark S. Does hepatic metabolism of melatonin affect the endogenous serum melatonin level in man?. J. Endocrinol. Invest. 2002, 25:489.
207. Ma X., Idle J.R., Krausz K.W., Gonzalez F.J. Metabolism of melatonin by human cytochromes p450. Drug Metab. Dispos. 2005, 33:489.
208. Patel C., Banerjee S., Ramachandran A.V. J. Cell Tissue Res. 2005, 5:353.
209. Ursing C., von Bahr C., Brismar K., Rojdmark S. Influence of cigarette smoking on melatonin levels in man. Eur. J. Clin. Pharmacol. 2005, 61:197.
210. Huunka K., Riotta A., Haataja R., Ylitalo P., Lelnonen E. Methods Find. Exp. Clin. Pharmacol. 2006, 28:447.
211. Bujkova B., Orendas P., Friedmanova L., Kassayova M., Detelinka I., Ahlersova E., Ahlers I. Prolonged melatonin administration in 6-month-old Sprague-Dawley rats: metabolic alterations. Acta Physiol. Hung. 2008, 95:65.
212. Semak I., Korik E., Antonova M., Wortsman J., Slominski A. Metabolism of melatonin by cytochrome P450s in rat liver mitochondria and microsomes. J. Pineal Res. 2008, 45:515.
213. Huyen T.T.T., Phuong H.L.T., Beom-Jin L. New findings on melatonin absorption and alterations by pharmaceutical excipients using the Ussing Chamber technique with mounted rat gastrointestinal segments. Int. J. Pharm. 2009, 378:9.
214. Anton-Tay F., Wurtman R.J. Regional uptake of 3H-melatonin from blood or cerebrospinal fluid by rat brain. Nature 1969, 221:474.
215. Vakkuri O., Leppaeluoto J., Kauppila A. Oral administration and distribution of melatonin in human serum, saliva and urine. Life Sci. 1985, 37:489.
216. Scagione F., Esposti D., Mariani M., Demartini G., Lucini V., Fraschini F. NATO ASI Ser. A Life Sci. 1995, 277. Pineal gland and its hormones.
217. Hidaka Y., Kato T. Jpn. Kokai Tokkyo Koho 1998, JP 10182455 A 19980707.
218. Merkus F.W.H.M. Eur. Pat. Appl. 1998, EP 867181 A1 19980930.
219. DeMuro R.L., Nafziger A.N., Blask D.E., Menhinick A.M., Bertino J.S. The absolute bioavailability of oral melatonin. J. Clin. Pharmacol. 2000, 40:781.
220. Liguori M., Pascarella R. 2001, Italy IT 1306019 B1 20010523.
221. McQuinn R.L., Benes L., Horriere F. Drug delivery to the oral cavity. Drug Pharm. Sci. 2005, 145:125.
222. Cao S., Liu Y., Mei X. Zhong. Yao. Zaz. (Beijing, China) 2006, 41:935.
223. Hussain S.A. Effect of melatonin on cholesterol absorption in rats. J. Pineal Res. 2007, 43:267.
224. Babu R.J., Dayal P., Singh M. Effect of cyclodextrins on the complexation and nasal permeation of melatonin. Drug Deliv. 2008, 15:381.
225. Bruno C., Jocelyne B., Guy C. The basic physiology and pathophysiology of melatonin. Sleep Med. Rev. 2005, 9:11.
226. Lynch H.J., Ozaki Y., Shakal V., Wurtman K.J. Melatonin excretion of man and rats: effect of time of day, sleep, pinealectomy and food consumption. Int. J. Biometeorol. 1975, 19:267.
227. Demidenko D.I. Dynamics of the serotonin content and melatonin and 5-hydroxy-indoleacetic acid excretion at the end of pregnancy, during normal labor and in labor anomalies. Vopr. Okhr. Matern. Detss. 1976, 21:63.
228. Gumoral'n, Regul. Rodovai Deyat. Lech. Ee Narushenii 1976, 23. V.I. Grishchenko (Ed.).
229. Gumoral'n, Regul. Rodovoi Deyat. Lech. Ee Narushenii 1976, 6. V.I. Grishchenko (Ed.).
230. Dudko L.V., Shcherbina N.A. Epiphyseal functional activity according to daily melatonin excretion data in the normal menstrual cycle. Pediatr. Akus. Ginek. 1977, 1:49.
231. Aakerstedt T., Froeberg J.E., Friberg Y., Wetterberg L. Melatonin excretion, body temperature and subjective arousal during 64 hours of sleep deprivation. Psychoneuroendocrinology 1979, 4:219.
232. Lemaitre B.J., Ollier-Hartmann M.P., Husson H.P., Hartmann L. Preliminary study of the synthesis, plasma circulation and urinary elimination of melatonin in man and the rat. Comp. Rend. Sean. Soc. Biolo. Fili. 1980, 174:661.
233. Alonso R., Ozaki Y., Wurtman R.J. Daily rhythms of melatonin in pineal, serum and urine of rats (author's transl). Reproduction 1980, 4:225.
234. Pineal function 1981, 143. C.D. Matthews, R.F. Seamark (Eds.).
235. Lang U., Komemark M., Aubert M.L., Paunier L., Sizonenko P.C. Radioimmunological determination of urinary melatonin in humans: correlation with plasma levels and typical 24-hour rhythmicity. J. Clin. Endocrinol. Metab. 1981, 53:645.
236. Labunets I.F., Grinevlch IuA., Kynsh I.T., Vasiluk A.N. Functional characteristics of the endocrine glands in skin melanoma patients. Vopr. Onkol. 1984, 30:14.
237. Vakkuri O., Leppaluoto J., Kauppila A. Oral administration and distribution of melatonin in human serum, saliva and urine. Life Sci. 1985, 37:489.
238. Penny R., Stanczyk F., Goebetsmann U. Melatonin: data consistent with a role in controlling ovarian function. J. Endocrinol. Invest. 1987, 10:499.
239. Kvetnoi I.M., Levin I.M. Daily excretion of melatonin in patients with cancer of the stomach and large intestine. Vopr. Onkol. 1987, 33:29.
240. Brun J., Claustrat B., David M. Urinary melatonin, LH, oestradiol, progesterone excretion during the menstrual cycle or in women taking oral contraceptives. Acta Endocrinol. 1987, 116:145.
241. Fernandez B., Malde J.L., Montero A., Acuna D. Pineal gland and gonadotropins: renal clearance rate of FSH, LH and melatonin in the fertile period and in peri- and postmenopausal women. Med. Sci. Res. 1988, 16:849.
242. Kennedy S.H., Brown G.M., Garfinkel P.E., McVey G., Parienti V. Sulphatoxy melatonin: an index of depression in anorexia nervosa and bulimia nervosa. Psychiatry Res. 1990, 32:221.
243. Fernandez B., Del Aguilla C.M., Castillo J.L., Montero A., Malde J.L., Castroviego D.A. Urinary excretion of melatonin and steroid metabolites during normal human pregnancy. Med. Sci. Res. 1993, 21:43.
244. Valtonen V., Laitinen J.T., Eriksson L. Renal melatonin excretion in sheep is enhanced by water dieresis. J. Endocrinol. 1993, 138:445.
245. Slowinska-Klencka D., Lewinski A. Role of melatonin in human physiology and pathology. I. Circadian rhythm of melatonin secretion. Involvement of melatonin in reproductive physiology. Melatonin and hypothalamic-pituitary-adrenal cortex axis. Post. Higi. Med. Dosw. 1993, 47:209.
246. Ekman A.C., Leppaluoto J., Huttunen P., Aranko K., Vakkuri O. Ethanol inhibits melatonin secretion in healthy volunteers in a dose-dependent randomized double blind cross-over study. J. Clin. Endocrinol. Metab. 1993, 77:780.
247. Saddier P., Brun J., Girard P., Claustrat B., Chasot G. Int. Congr. Ser. 1993, 1017:367. Melatonin and the Pineal Gland.
248. Perissin L., Zorzet S., Rapozzi V., Giraldi T. A non-invasive simple method for measurement of urinary excretion of melatonin in undisturbed mice. J. Pineal Res. 1993, 15:138.
249. Chan T.Y., Tang P.L. J. Endocrinol. Invest. 1999, 22:527.
250. Baskett J.J., Cockrem J.F., Antunovich T.A. Sulphatoxymelatonin excretion in older people: relationship to plasma melatonin and renal function. J. Pineal Res. 1998, 24:58.
251. Stoschitzky K., Sakotnik A., Lercher P., Zwelker R., Maier R., Liebmann P., Lindner W. Influence of beta-blockers on melatonin release. Eur. J. Clin. Pharmacol. 1999, 55:111.
252. Wetterberg L., Bergiannaki J.D., Paparrigopoulos T., von Knorring L., Eberhard G., Bratlid T., Yuwiler A. Normative melatonin excretion: a multinational study. Psychoneuroendocrinology 1999, 24:209.
253. Kennaway D.J., Lushington K., Dawson D., Lack L., Van Den Heuvei C., Rogers N. Urinary 6-sulfatoxymelatonin excretion and aging: new results and a critical review of the literature. J. Pineal Res. 1999, 27:210.
254. Bylesjo I., Forsgren L., Wetterberg L. Melatonin and epileptic seizures in patients with acute intermittent porphyria. Epileptic Disord. 2000, 2:203.
255. Miller H.L., Ekstrom R.D., Mason G.A., Lydiard R.B., Golden R.N. Noradrenergic function and clinical outcome in antidepressant pharmacotherapy. Neuropsychopharmacology 2001, 24:617.
256. Griefahn B., Broede P., Remer T., Blaszkewicz M. Excretion of 6-hydroxymelatonin sulfate (6-OHMS) in siblings during childhood and adolescence. Neuroendocrinology 2003, 78:241.
257. Neuman A., Gothilf Y., Haim A., Ben-Aharon G., Zisapel N. Nocturnal patterns and up-regulated excretion of the melatonin metabolite 6-sulfatoxymelatonin in the diurnal rodent Psammomys obesus post-weaning under a short photoperiod. Comp. Biochem. Phys. A 2005, 142A:297.
258. Carvalho L.A., Gorenstein C., Moreno R.A., Markus R.P. Melatonin levels in drug-free patients with major depression from the southern hemisphere. Psychoneuroendocrinology 2006, 31:761.
259. Hughes M.R., Kitamura N., Bennett D.C., Gray D.A., Sharp P.J., Poon A.M.S. Effect of melatonin on salt gland and kidney function of gulls, Larus glaucescens. Gen. Comp. Endocrinol. 2007, 151:300.
260. Supnewski J., Isztal M., Marczynski T. Acta Physiol. Pol. 1960, 11:892.
261. Barchas J., DaCosta F., Spector S. Acute pharmacology of melatonin. Nature 1967, 214:919.
262. Smith J.A. Advances in the bioscience (Oxford), Melatonin. Curr. Status Perspect. 1981, 29:113.
263. Smith J.A. Advances in the bioscience (Oxford), Melatonin. Curr. Status Perspect. 1981, 29:45.
264. Arushanyan E.B. The pharmacology of melatonin. Eksperimental"naia i klinicheskaia farmakologiia 1992, 55:72.
265. Melatonin 1993, 513. Y. Hing-Sing, R.J. Reiter (Eds.).
266. Scaglione F., Esposti D., Marlani M., Demartini G., Lucini V., Fraschini F. NATO ASI series, series A: pineal gland and its hormones. Life Sci. 1995, 277:155.
267. Geoffriau M., Brun J., Chazot G., Claustrat B. The physiology and pharmacology of melatonin in humans. Horm. Res. 1998, 49:136.
268. Kulkami S.K., Shaji A.V. Methods Find. Exp. Clin. Pharmacol. 1998, 20:237.
269. Cardinali D.P., Golombek D.A., Rosenstein R.E., Cutrera R.A., Esquifino A.I. Melatonin site and mechanism of action: single or multiple?. J. Pineal Res. 1997, 23:32.
270. Von Gall C., Stehle J.H., Weaver D.R. Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res. 2002, 309:151.
271. Carrillo-Vico A., Garcia-Perganeda A., Naji L. Expression of membrane and nuclear melatonin receptor mRNA and protein in the mouse immune system. Cell. Mol. Life Sci. 2003, 60:2272.
272. Garratt P.J., Jones R., Tocher D.A., Sugden D. Mapping the melatonin receptor. 3. Design and synthesis of melatonin agonists and antagonists derived from 2-phenyltryptamines. J. Med. Chem. 1995, 38:1132.
273. Browing C., Beresford I., Fraser N., Giles H. Pharmacological characterization of human recombinant melatonin mt(1) and MT(2) receptors. Br. J. Pharmacol. 2000, 129:877.
274. Sugden D., Chong N.W., Lewis D.F. Structural requirements at the melatonin receptor. Br. J. Pharmacol. 1995, 114:618.
275. Lewis D.F.V., Arendt J., English J. Quantitative structure-activity relationships within a series of melatonin analogs and related indolealkylamines. J. Pharmacol. Exp. Ther. 1990, 252:370.
276. Barett P., Conway S., Jockers R., Strosberg A.D., Guardiola-Lemaitre B., Delagrange P., Morgan P.J. Biochim. Biophys. Acta Mol. Cell Res. 1997, 1356:299.
277. Mitchell N.C., Darsey J., Compadre R.L. 2004.
278. Rivara S., Diamantini G., Di Glacomo B., Lamba D., Gatti G., Lucini V., Pannacci M., Mor M., Spadoni G., Tarzla G. Reassessing the melatonin pharmacophore-enantiomeric resolution, pharmacological activity, structure analysis, and molecular modeling of a constrained chiral melatonin analogue. Bioorg. Med. Chem. 2006, 14:3383.
279. Hirsch-Rodriguez E., Imbesi M., Manev R., Uz T., Manev H. The pattern of melatonin receptor expression in the brain may influence antidepressant treatment. Med. Hypotheses 2007, 69:120.
280. Czeisler C.A., Shanahan T.L., Klerman B., Martens H., Brotman D.J., Emens J.S., Klein T., Rizzo J.F. Suppression of melatonin secretion in some blind patients by exposure to bright light. N. Engl. J. Med. 1995, 332:6.
281. Lockley S.W., Skene D.J., Thapan K., English J., Ribeiro D., Haimov I., Hampton S., Middleton B., von Schantz M., Arendt J. Extraocular light exposure does not suppress plasma melatonin in humans. J. Clin. Endocrinol. Metab. 1998, 83:3369.
282. Touitou Y., Le Hoang P., Claustrat B., Attye T., Auzeby A., Brun J., Bogdan A., Touitou C. Decreased nocturnal plasma melatonin peak in patients with a functional alteration of the retina in relation with uveitis. Neurosci. Lett. 1986, 70:170.
283. Portaluppi F., Cortelli P., Avoni P., Vergnani L., Maltoni P., Pavani A., Sforza E., Degli Uberti E.C., Gambetti P., Lugaresi E. Progressive disruption of the circadian rhythm of melatonin in fatal familial insomnia. J. Clin. Endocrinol. Metab. 1994, 78:1075.
284. De Leersnyder H., De Biois M.C., Claustrat B., Romana S., Albrecht U., Von Kleist-Retzow J.C., Delobel B., Viot G., Lyonnet S., Vekemans M., Munnich A. Inversion of the circadian rhythm of melatonin in the Smith-Magenis syndrome. J. Pediatr. 2001, 139:111.
285. Fiorina P., Lattuda G., Silvestrini C., Ponari O., Dall'Aglio P. Disruption of nocturnal melatonin rhythm and immunological involvement in ischaemic stroke patients. Scand. J. Immunol. 1999, 50:228.
286. Pang S.F., Li Y., Jiang D.H., Chang B., Xie B.L. Acute cerebral hemorrhage changes the nocturnal surge of plasma melatonin in humans. J. Pineal Res. 1990, 9:193.
287. Molina-Carballo A., Munoz-Hoyos A., Reiter R.J., Sánchez-Forte M., Moreno-Madrid F., Rufo-Campos M., Molina-Font J.A., Acuña-Castroviejo D. Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy: two years' experience. J. Pineal Res. 1997, 23:97.
288. Sheldon S.H. Pro-convulsant effects of oral melatonin in neurologically disabled children. Lancet 1998, 351:1254.
289. Tetsuo M., Pollinsky R.J., Markey S.P., Koplin I.J. Urinary 6-hydroxymelatonin excretion in patients with orthostatic hypotension. J. Clin. Endocrinol. Metab. 1981, 53:607.
290. Bruce J., Tamarkin L., Riedel C., Markey S., Oldfield E. Sequential cerebrospinal fluid and plasma sampling in humans: 24-hour melatonin measurements in normal subjects and after peripheral sympathectomy. J. Clin. Endocrinol. Metab. 1991, 72:819.
291. O'Brien I.A.D., lewin I.G., O'Hare J.P., Arendt J., Corrall R.J. Abnormal circadian rhythm of melatonin in diabetic autonomic neuropathy. Clin. Endocrinol. 1986, 24:359.
292. Zeitzer J.M., Ayas N.T., Shea S.A., Brown R., Czeisler C.A. Absence of detectable melatonin and preservation of cortisol and thyrotropin rhythms in tetraplegia. J. Clin. Endocrinol. Metab. 2000, 85:2189.
293. Melatonin: Biological Basis of Its Function in Health and Disease 2005, 218. Landes Bioscience, Georgetown, TX. S.R. Pandi-Perumal, D.P. Cardinall (Eds.).
294. Claustrat B., Brun J., Chiquet C. Secretion is supersensitive to light in Migraine. Cephalagia 2004, 24:128.
295. Zurak N. Role of the suprachiasmatic nucleus in the pathogenesis of migraine attacks. Cephalagia 1997, 17:128.
296. Claustrat B., Chazol G., Brun J. A chronobiological study of melatonin and cortisone secretion in depressed subjects: plasma melatonin biochemical marker in major depression. Biol. Psychiatry 1984, 19:1215.
297. Catecholamines: Basic and Clinical Frontiers 1978, vol. II:1173. Pergamon, Oxford. E. Usdin, I.J. Koplin, J. Barchas (Eds.).
298. Voderholzer U., Laakmann G., Becker U. Circadian profiles of melatonin in melancholic depressed patients and healthy subjects in relation to cortisone secretion and sleep. Psychiatr. Res. 1997, 71:151.
299. Arendt J., Bhanji S., Franey C., Mattingly D. Plasma melatonin level in anorexia nervosa. Br. J. Psychiatry 1992, 161:361.
300. Wu Y.H., Feenstra M.G., Zhou J.N. Molecular changes underlying reduced pineal melatonin level in Alzheimer disease: alterations in preclinical and clinical stages. J. Clin. Endocrinol. Metab. 2003, 88:5898.
301. Brugger P., Markti W., Herold M. Impaired nocturnal secretion of melatonin in coronary heart disease. Lancet 1995, 345:140.
302. Domínguez-Rodríguez A., Abreu-González P., García M.J., Sanchez J., Marrero F., de Armas-Trujillo D. Decreased nocturnal melatonin levels during acute myocardial infarction. J. Pineal Res. 2002, 33:248.
303. Harris A.S., Burgess H.J., Dawson D. The effect of day time exogenous melatonin administration on cardiac autonomic activity. J. Pineal Res. 2001, 31:199.
304. Holmes S.W., Sugden D. The effect of melatonin on pinealectomy-induced hypertension in the rat. Br. J. Pharmacol. 1976, 56:360.
305. Jonas M., Garfinkel D., Sisapel N. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Press. 2003, 12:19.
306. Scheer F.A., Van Montfrans G.A., Van Someren E.J. Daily night time melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 2004, 43:192.
307. Lusardt P., Piazza E., Fogan R. Cardiovascular effects of melatonin in hypertensive patients well controlled by nifidepine: 24-hr study. Br. J. Clin. Pharmacol. 2000, 49:423.
308. Claustrat B., Ban J., Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med. Rev. 2005, 9:11.
309. Guerrero J.M., Reiter R.J. Melatonin immune system relationships. Curr. Top. Med. Chem. 2002, 2:167.
310. Withyachumnamkul B., Nonaka K.O., Santana C. Interferon-gamma modulates melatonin production in rat pineal glands in organ culture. J. Interteron Res. 1990, 10:403.
311. Sutherland E.R., Martin R.J., Ellison M.C., Kraft M. Immuno modulatory effect of melatonin in asthma. Am. J. Respir. Crit. Care Med. 2002, 166:1055.
312. Sulli A., Maestroni G.J.M., Villaggio B. Melatonin serum levels in rheumatoid arthritis. Ann. N. Y. Acad. Sci. 2002, 966:276.
313. Bartsch H., Bartsch C. Effect of melatonin on experimental tumors under different photoperiods and time of administration. J. Neural Transm. 1981, 52:269.
314. Lissoni P., Chilelli M., Villa S. Five year survival in metastatic non-small lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J. Pineal Res. 2003, 35:12.
315. Karbownik M., Lewinski A., Reiter R.J. Anticarcinogenic action of melatonin which involve antooxidative process: comparison with other antioxidants. Int. J. Biochem. Cell Biol. 2001, 33:735.
316. Blask D.E., Saucer L.A., Danchy R.T. Melatonin as achronobiotic/anticancer agent. Curr. Top. Med. Chem. 2002, 2:113.
317. Blask D.E., Saucer L.A., Dauchy R.T., Holowachak F.W., Ruhoff M.S., Kopff H.S. Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acids metabolism via melatonin receptor mediated signal transduction events. Cancer Res. 1999, 59:4693.
318. Elmegeed G.A., Bainomy A.K., Abdel-Salam O.M.E. Evaluation of anti-inflammatory and anti-noceciptive activities of novel synthesized melatonin analogues. J. Med. Chem. 2007, 42:1285.
319. Cowen P.J., Fraser S., Sammons R., Green A.R. Atenolol reduces plasma melatonin concentration in man. Br. J. Clin. Pharmacol. 1983, 15:579.
320. Cowen P.J., Bevan J.S., Gosden B., Elliott S.A. Treatment with β-adrenoreceptor blockers reduces plasma melatonin concentration. Br. J. Clin. Pharmacol. 1985, 19:258.
321. David E.B. Melatonin sleep disturbance and cancer risk. Sleep Med. Rev. 2009, 13:257.
322. Van Den Heuvel C.J., Ferguson S.A., Macchi M.M., Dawson D. Melatonin as hypnotic. Sleep Med. Rev. 2005, 9:71.